MARKET

ANNX

ANNX

Annexon, Inc.
NASDAQ
4.960
-0.040
-0.80%
Pre Market: 4.960 0 0.00% 04:11 03/31 EDT
OPEN
5.01
PREV CLOSE
5.00
HIGH
5.14
LOW
4.855
VOLUME
120
TURNOVER
0
52 WEEK HIGH
7.18
52 WEEK LOW
1.285
MARKET CAP
795.95M
P/E (TTM)
-3.5707
1D
5D
1M
3M
1Y
5Y
1D
Annexon: Solid Cash Runway and 2026 Clinical Catalysts Underpin Buy Rating
TipRanks · 1h ago
ANNEXON INC FILES FOR MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING
Reuters · 1h ago
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX), Innovent Biologics (OtherIVBXF) and Sino Biopharmaceutical (OtherSBMFF)
TipRanks · 11h ago
Annexon (ANNX): Late‑Stage Complement Pipeline and Strong Cash Runway Support Attractive Risk‑Reward and Buy Rating
TipRanks · 12h ago
Annexon reports Q4 EPS (28c), consensus (32c)
TipRanks · 15h ago
Annexon Q4 EPS $(0.28) Beats $(0.32) Estimate
Benzinga · 16h ago
Annexon FY25 net loss widens 50.9% to $208.5 million; R&D expenses climb to $184.7 million
Reuters · 16h ago
Annexon Biosciences GAAP EPS of -$0.28 beats by $0.04
Seeking Alpha · 16h ago
More
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.

Webull offers Annexon Inc stock information, including NASDAQ: ANNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANNX stock methods without spending real money on the virtual paper trading platform.